Oleptro

Oleptro is a brand name of trazodone, approved by the FDA in the following formulation(s):

OLEPTRO (trazodone hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: ANGELINI LLC
  
  Approval date: February 2, 2010
  
  Strength(s): 150MG ^[RLD], 300MG
  

Has a generic version of Oleptro been approved?

No. There is currently no therapeutically equivalent version of Oleptro available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oleptro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
  Patent 6,607,748
  Issued: August 19, 2003
  Inventor(s): Vincent; Lenaerts & Roland Herwig Friedrich; Beck & Elsie; Van Bogaert & Francois; Chouinard & Reiner; Höpcke & Cyril; Désévaux
  The present invention relates to a novel form of cross-linked high amylose starch and processes for its manufacture. Such cross-linked high amylose starch is useful as an excipient in a controlled-release pharmaceutical formulation when compressed with pharmaceutical agent(s) in a tablet. Such cross-linked high amylose starch is prepared by (a) cross-linking and chemical modification of high amylose starch, (b) gelatinization, and (c) drying to obtain a powder of said controlled release excipient. In a preferred embodiment, such cross-linked high amylose starch is prepared in the following steps: (1) granular cross-linking and additional chemical modification (e.g., hydroxypropylation) of high-amylose starch; (2) thermal gelatinization of the starch from step (1); and (3) drying the starch from step (2) to yield a powder capable of being used as a controlled release excipient.
  
  Patent expiration dates:
  
  
  • June 29, 2020
    
    ✓ 
    Drug product
  
  



• 
  Trazodone composition for once a day administration
  Patent 7,829,120
  Issued: November 9, 2010
  Inventor(s): Gervais; Sonia & Smith; Damon & Rahmouni; Miloud & Contamin; Pauline & Ouzerourou; Rachid & Ma; My Linh & Ferrada; Angela & Soulhi; Fouzia
  Assignee(s): Labopharm Inc.
  Labopharm Europe Limited
  Labopharm (Barbados) Limited
  The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
  
  Patent expiration dates:
  
  
  • March 27, 2027
    
    ✓ 
    Patent use: METHOD OF TREATING DEPRESSION
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • February 2, 2013 - NEW DOSAGE FORM
  
  

See also...

• Oleptro Consumer Information (Drugs.com)
• Oleptro Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Oleptro Consumer Information (Cerner Multum)
• Oleptro Advanced Consumer Information (Micromedex)
• Trazodone Consumer Information (Drugs.com)
• Trazodone Consumer Information (Wolters Kluwer)
• Trazodone Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Trazodone Consumer Information (Cerner Multum)
• Trazodone Advanced Consumer Information (Micromedex)
• Trazodone Hydrochloride AHFS DI Monographs (ASHP)

Colestilan

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0095522-45-5

Chemical Formula

(C4-H6-N2·C3-H5-Cl-O)n

Therapeutic Category

Antilipemic agent

Chemical Names

1H-Imidazole, 2-methyl-, polymer with (chloromethyl)oxirane (USAN)

2-Methylimidazole polymer with 1-chloro-2,3-epoxypropane (WHO)

2-Methylimidazole-epichlorohydrin copolymer (JAN)

Epichlorohydrin-2-methylimidazole copolymer

Oxirane, (chloromethyl)-, polymer with 2-Methyl-1H-imidazole (USAN)

Poly[2-methylimidazol-co-(chlormethyl)oxiran] (1:1)

Foreign Names

• Colestilanum (Latin)
• Colestilan (German)
• Colestilan (French)
• Colestilan (Spanish)

Generic Names

• Colestilan Chloride (OS: USAN)
• Colestimide (OS: JAN)
• MCI-196 (IS)

Brand Names

• Cholebine
  Tanabe Mitsubishi, Japan



• Cholebine-Mini
  Tanabe Mitsubishi, Japan

International Drug Name Search

Glossary

IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Alginate de sodium / Bicarbonate de sodium Teva

Alginate de sodium/Bicarbonate de sodium Teva may be available in the countries listed below.

Ingredient matches for Alginate de sodium/Bicarbonate de sodium Teva

Sodium Alginate

Sodium Alginate is reported as an ingredient of Alginate de sodium/Bicarbonate de sodium Teva in the following countries:

• France

Sodium Bicarbonate

Sodium Bicarbonate is reported as an ingredient of Alginate de sodium/Bicarbonate de sodium Teva in the following countries:

• France

International Drug Name Search

Bruxicam

Bruxicam may be available in the countries listed below.

Ingredient matches for Bruxicam

Piroxicam

Piroxicam is reported as an ingredient of Bruxicam in the following countries:

• Georgia


• Italy


• Malta


• Romania

International Drug Name Search

Broncho Saline inhalation

Generic Name: sodium chloride (inhalation) (SOE dee um KLOR ide)

Brand Names: Broncho Saline, Hyper-Sal, Sodium Chloride, Inhalation

What is Broncho Saline (sodium chloride (inhalation))?

Sodium chloride is the chemical name for salt. Sodium chloride can reduce some types of bacteria in certain body secretions, such as saliva.

Sodium chloride inhalation is used to produce sputum (mucus, or phlegm) from the mouth in order to collect it for medical testing. This medication may also be used to dilute other medications inhaled through a nebulizer.

Sodium chloride inhalation may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about Broncho Saline (sodium chloride (inhalation))?

Before using sodium chloride inhalation, tell your doctor if you have asthma, congestive heart failure, heart disease, high blood pressure, epilepsy, kidney or liver disease, migraine headaches, any type of edema (swelling), if you have recently had surgery, or if you are on a low-salt diet.

Tell your doctor about all other medications you use, especially potassium supplements, diuretics, steroids, blood pressure medications, or medications that contain sodium (such as Alka-Seltzer or Zegrid).

Tell your caregivers at once if you have a serious side effect such as chest pain, trouble breathing, swelling in your hands or feet, feeling like you might pass out, tired feeling, muscle twitching, confusion, uneven heart rate, extreme thirst, increased or decreased urination, leg discomfort, muscle weakness or limp feeling.

What should I discuss with my health care provider before using Broncho Saline (sodium chloride (inhalation))?

You should not use this medication if you have ever had an allergic reaction to sodium chloride inhalation.

If you have certain conditions, you may need a dose adjustment or special tests to safely use this medication. Before using sodium chloride inhalation, tell your doctor if you have:

• 
  

  asthma;

  
  


• 
  

  congestive heart failure;

  
  


• 
  

  heart disease or high blood pressure;

  
  


• 
  

  epilepsy;

  
  


• 
  

  kidney or liver disease;

  
  


• 
  

  migraine headaches;

  
  


• 
  

  any type of edema (swelling);

  
  


• 
  

  if you have recently had surgery; or

  
  


• 
  

  if you are on a low-salt diet.

  
  

FDA pregnancy category C. It is not known whether sodium chloride inhalation is harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether sodium chloride inhalation passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How is sodium chloride inhalation given?

Use this medication exactly as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended. Follow the directions on your prescription label.

Sodium chloride inhalation is given using a nebulizer. You will inhale the medication through a face mask, mouth piece, or other device connected to the nebulizer.

Your doctor, nurse, or other healthcare provider can show you how to properly use the nebulizer.

Sodium chloride is a liquid that is placed into the medication chamber of the nebulizer. A mouthpiece or face mask is then attached to the drug chamber, along with an air compressor.

To prepare for inhaling sodium chloride through a nebulizer, you may be given another inhaled medication to prevent bronchospasm (muscle contractions within the airways of the lungs). Your doctor may also ask you to blow your nose, rinse your mouth with water, or wipe the inside of your mouth with a tissue. Follow your doctor's instructions carefully for best results.

In most cases, you will use this medication while you are sitting upright in a comfortable position. Breathe slowly and evenly while you are using the mask, mouthpiece, or other breathing device. You may also be given a nose clip to wear that will close your nasal passages so that you inhale only through your mouth.

If you are using this medication as part of a sputum test, you will need to spit about every 5 minutes or as directed by your healthcare provider. Cough deeply from your chest to produce an optimal specimen for testing.

Continue breathing through the nebulizer for as long as directed by your doctor. Once you have completed the inhalation for the prescribed amount of time, throw away any liquid that is left in the medicine chamber. Do not save it for later use.

If you store sodium chloride at home, keep it at room temperature away from moisture and heat.

What happens if I miss a dose?

Since sodium chloride inhalation is sometimes used only as needed, you may not be on a dosing schedule. If you are using the medication regularly, use the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to use the medicine and skip the missed dose. Do not use extra medicine to make up the missed dose.

What happens if I overdose?

Tell your caregivers at once if you think you have used too much of this medicine.

Overdose symptoms may include increased thirst, drowsiness, restless feeling, confusion, muscle pain or weakness, nausea, vomiting, increased urination, fast heart rate, fainting, and seizure (convulsions).

What should I avoid after receiving Broncho Saline (sodium chloride (inhalation))?

Follow your doctor's instructions about any restrictions on food, beverages, or activity after using sodium chloride inhalation.

Broncho Saline (sodium chloride (inhalation)) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Tell your caregivers at once if you have a serious side effect such as:

• 
  

  chest pain, trouble breathing;

  
  


• 
  

  feeling like you might pass out;

  
  


• 
  

  swelling in your hands or feet;

  
  


• 
  

  tired feeling, muscle twitching;

  
  


• 
  

  confusion, uneven heart rate, extreme thirst, increased or decreased urination, leg discomfort, muscle weakness or limp feeling.

  
  

Less serious side effects may include a salty taste or slight burning or irritation in your mouth.

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Broncho Saline (sodium chloride (inhalation))?

Tell your doctor about all other medications you use, especially:

• 
  

  potassium supplements;

  
  


• 
  

  a diuretic (water pill);

  
  


• 
  

  a steroid such as prednisone, fluticasone (Advair), mometasone (Asmanex, Nasonex), dexamethasone (Decadron, Hexadrol) and others;

  
  


• 
  

  blood pressure medications; or

  
  


• 
  

  medications that contain sodium, such as Alka-Seltzer or Zegrid (omeprazole and sodium bicarbonate).

  
  

This list is not complete and there may be other drugs that can interact with sodium chloride inhalation. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

More Broncho Saline resources

• Broncho Saline Drug Interactions
• 0 Reviews · Be the first to review/rate this drug

Where can I get more information?

• Your doctor or pharmacist can provide more information about sodium chloride inhalation.

Oxalin

Oxalin may be available in the countries listed below.

Ingredient matches for Oxalin

Oxacillin

Oxacillin is reported as an ingredient of Oxalin in the following countries:

• Romania

Oxymetazoline

Oxymetazoline hydrochloride (a derivative of Oxymetazoline) is reported as an ingredient of Oxalin in the following countries:

• Poland

International Drug Name Search

Teva Carbi-Levo

Teva Carbi-Levo may be available in the countries listed below.

Ingredient matches for Teva Carbi-Levo

Carbidopa

Carbidopa is reported as an ingredient of Teva Carbi-Levo in the following countries:

• South Africa

Levodopa

Levodopa is reported as an ingredient of Teva Carbi-Levo in the following countries:

• South Africa

International Drug Name Search